newsfilter
← Latest News
GlobeNewswire·

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGN
  • Exagen Inc. announced a new systematic review published in Lupus Science & Medicine demonstrating AVISE Lupus algorithm superiority over conventional serologic tests.
  • The analysis included biomarker data for 3,132 individuals from 14 academic medical centers collected between 2011 and 2025.
  • AVISE Lupus uniquely identified approximately 25% of SLE patients who would otherwise be missed by conventional markers such as anti-dsDNA, anti-Smith, C3, and C4.
  • The algorithm demonstrated an AUC up to 0.90, specificity above 98%, and unprecedented likelihood ratios across more than 1,200 SLE patients.
  • The study supports earlier, more definitive SLE diagnosis with potential benefits for earlier intervention, prevention of organ damage, and improved long-term outcomes.
  • Over 1 million patients have been tested with AVISE Lupus since its launch in 2012, providing an extensive real-world evidence base.
  • The findings reinforce Exagen's intellectual property barriers and competitive position in the autoimmune diagnostics market.